OTIC Otonomy, Inc.

12.65
-0.40  -3%
Previous Close 13.05
Open 13.10
Price To book 2.33
Market Cap 382.74M
Shares 30,256,000
Volume 86,809
Short Ratio 12.41
Av. Daily Volume 165,133

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Second Phase 3 trial initiated March 2016. Data due 3Q 2017.
OTO-104 AVERTS-1
Ménière's disease
Phase 2 trial to be initiated 2H 2017.
OTO-311
Tinnitus
Second Phase 3 trial initiated March 2016. Data due by the end of 2017.
OTO-104 AVERTS-2
Ménière's disease
Phase 2 trial completed October 2016. End of Phase 2 meeting planned with FDA 2Q 2017.
OTIPRIO
Pediatric patients with acute otitis media with tympanostomy tubes (AOMT)
Phase 2 trial initiation announced January 19, 2017.
OTO-104
Prevention of hearing loss in cancer patients undergoing chemotherapy
Approved December 11, 2015
OTIPRIO (ciprofloxacin otic suspension)
Ear Tube Placement Surgery
Phase 3 trial met primary endpoint - January 5, 2017. sNDA filing submitted March/April 2017.
OTIPRIO
Acute otitis externa